Allergy Therapeutics (AGY) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Mar 2023 07:00 AM
RNS
Publication of Interim Results Delayed
27 Mar 2023 07:00 AM
RNS
Patients dosed in VLP Peanut PROTECT trial
08 Mar 2023 05:28 PM
RNS
Block Listing Interim Review
03 Mar 2023 07:00 AM
RNS
PDMR Dealing
07 Feb 2023 06:29 PM
RNS
Result of AGM
20 Jan 2023 07:00 AM
RNS
Half-Year Trading Update 2023
13 Jan 2023 05:27 PM
RNS
NOTICE OF 2022 ANNUAL GENERAL MEETING
29 Dec 2022 11:05 AM
RNS
Second Price Monitoring Extn
29 Dec 2022 11:00 AM
RNS
Price Monitoring Extension
29 Dec 2022 09:05 AM
RNS
Second Price Monitoring Extn
29 Dec 2022 09:00 AM
RNS
Price Monitoring Extension
29 Dec 2022 07:00 AM
RNS
Annual Report and Accounts Delayed
28 Dec 2022 07:00 AM
RNS
Director Resignation
08 Dec 2022 07:00 AM
RNS
Key updates on Grass MATA MPL and VLP Peanut
06 Dec 2022 07:00 AM
RNS
Appointment of Non-Executive Directors
21 Nov 2022 07:00 AM
RNS
Appointment of Interim CFO
28 Oct 2022 07:00 AM
RNS
Allergy to resume UK manufacturing production
19 Oct 2022 03:39 PM
RNS
Holding(s) in Company
17 Oct 2022 01:27 PM
RNS
Allergy Therapeutics - Result of GM
04 Oct 2022 07:00 AM
RNS
UK manufacturing update
29 Sep 2022 12:00 PM
RNS
Allergy Therapeutics at Investor Meet Company
29 Sep 2022 07:00 AM
RNS
Subscription and Debt Financing
29 Sep 2022 07:00 AM
RNS
Unaudited Preliminary Results 2022
05 Sep 2022 07:00 AM
RNS
Allergy Therapeutics at H.C. Wainwright Conference
02 Sep 2022 04:50 PM
RNS
Total Voting Rights
02 Aug 2022 12:58 PM
RNS
Block Listing Interim Review
15 Jul 2022 07:00 AM
RNS
Trading Update and Notice of Results
01 Jul 2022 07:00 AM
RNS
Allergy Therapeutics at EAACI Congress 2022
26 May 2022 07:00 AM
RNS
Nick Wykeman to step down as CFO
23 May 2022 07:00 AM
RNS
Allergy Therapeutics at H.C. Wainwright Conference
25 Apr 2022 07:00 AM
RNS
Allergy Therapeutics shares data at WAO-BSACI
08 Mar 2022 07:00 AM
RNS
Allergy Therapeutics at Cowen Health Conference
07 Mar 2022 07:00 AM
RNS
Allergy Therapeutics at Investor Meet Company
03 Mar 2022 07:00 AM
RNS
Allergy Therapeutics plc - Interim Results
01 Mar 2022 07:00 AM
RNS
Allergy Therapeutics shares positive new data
24 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
24 Feb 2022 04:36 PM
RNS
Price Monitoring Extension
24 Feb 2022 02:06 PM
RNS
Second Price Monitoring Extn
24 Feb 2022 02:01 PM
RNS
Price Monitoring Extension
02 Feb 2022 11:05 AM
RNS
Secures new revolving credit facility
01 Feb 2022 02:16 PM
RNS
Total Voting Rights
26 Jan 2022 07:00 AM
RNS
FDA clearance of IND application for VLP Peanut
24 Jan 2022 01:13 PM
RNS
Holding(s) in Company
13 Jan 2022 07:00 AM
RNS
Half Year Trading Update & Notice of Results
05 Jan 2022 08:47 AM
RNS
Total Voting Rights
25 Nov 2021 09:17 AM
RNS
Allergy Therapeutics: Granting of Awards
23 Nov 2021 12:54 PM
RNS
Result of AGM
11 Nov 2021 07:00 AM
RNS
Director Dealings
27 Oct 2021 07:00 AM
RNS
Cheryl MacDiarmid appointed to Board of Directors
25 Oct 2021 09:00 AM
RNS
Price Monitoring Extension

Allergy Therapeutics plc is a UK international biotechnology company focused on the treatment and diagnosis of allergic disorders.

Headquartered in Worthing, it develops and sells aluminum-free allergy vaccines, both injectable and sublingual, for conditions like hay fever and peanut allergies.

Allergy Therapeutics share price launched at 34p in 2004.

UK 100

Latest directors dealings